Codagenix is a privately held, biotechnology company based in Stony Brook, New York. The company focuses on constructing live-attenuated viral vaccines against multiple targets using the company's proprietary technology platform, SAVE. Standing for Synthetic Attenuated Virus Engineering, the platform relies on synthetic biology and the rational 're-design' of a target virus' entire genome to yield a vaccine strain. The customization process uses software-based algorithms to 're-code' the genome of a target virus.
In February 2020, the company teamed up with the Serum Institute of India to co-develop a live-attenuated vaccine for COVID-19. The company uses viral deoptimization technology in order to create multiple vaccine candidates for a virus.
Co-Founder, Senior Scientific Officer
J. Robert Coleman
Co-Founder & COO
Co-Founder, President, and Chief Scientific Officer
Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19
February 13, 2020
Xconomy: With $2M, Codagenix Becomes Accelerate LI's First VC-Backed Grad
Documentaries, videos and podcasts
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.